Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
47.31
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
45
46
Next >
Current Analysis: Bristol-Myers Squibb
October 04, 2023
Over the past year, Bristol’s share price dropped about 20.3% from $71.21 to $56.73 as of Wednesday’s market close.
Via
Talk Markets
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration
Via
Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
October 02, 2023
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.
Via
InvestorPlace
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
October 02, 2023
The stars are aligning for these pharmaceutical giants, making their stocks look ready to run higher in next year.
Via
InvestorPlace
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
October 02, 2023
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices.
Via
Benzinga
Bristol-Myers Squibb Unusual Options Activity For September 27
September 27, 2023
Via
Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
September 18, 2023
Via
Benzinga
2 Undervalued Dividend Stocks to Buy Now
September 13, 2023
These two pharma titans are proven income vehicles.
Via
The Motley Fool
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
September 28, 2023
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation
Via
Benzinga
3 Dividend Stocks to Buy and Hold Until Retirement
September 28, 2023
Together, these stocks can also help diversify your portfolio by giving you exposure to different industries.
Via
The Motley Fool
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
September 25, 2023
None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
September 24, 2023
These three healthcare stocks to sell are waving red flags at investors who should pay attention or suffer the consequences.
Via
InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...
Via
Talk Markets
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
September 22, 2023
Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy...
Via
Benzinga
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 18, 2023
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2023
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
September 14, 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now.
Via
InvestorPlace
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth
September 14, 2023
Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein
Via
Benzinga
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.
September 13, 2023
Roz Brewer stepped down from leading Walgreens, and the next CEO is a tough choice. These three make the cut.
Via
InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
September 12, 2023
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p
Via
Benzinga
Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
September 11, 2023
Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo...
Via
Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
September 11, 2023
This story was first published on the Benzinga India portal.
Via
Benzinga
The 3 Best Pharma Stocks to Buy Now: September 2023
September 08, 2023
There are pharma stocks to buy for each type of investor. This article explores the best options in the industry.
Via
InvestorPlace
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug
September 07, 2023
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
September 06, 2023
President Joe Biden’s Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs, remains the talk of the town as investors sell off shares in pharmaceutical...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
September 05, 2023
Via
Benzinga
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
September 05, 2023
On Friday, Judge Thomas Rose, serving in the U.S.
Via
Benzinga
3 No-Brainer Dividend Stocks to Buy in September
September 02, 2023
Income investors should really like these biopharma stocks with juicy dividends.
Via
The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?
Via
The Motley Fool
3 Undervalued Healthcare Stocks In 2023
August 31, 2023
These 3 undervalued healthcare stocks in 2023 are attractive today for their attractive valuations and total return potential.
Via
Talk Markets
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.